An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

This study is specifically for people who have already taken part in certain previous etrasimod studies (known as APD334-301, APD334-302, or APD334-210) for ulcerative colitis.

To be eligible, you must have completed a certain point in your previous study. For example, if you were in study APD334-301 or APD334-210, you needed to have completed at least week 12 and your ulcerative colitis was still active or had worsened, or you completed the full 52 weeks of the study. If you were in study APD334-302, you needed to have completed at least week 12.

You would not be able to join this extension study if your doctor felt it wasn't suitable for you for any reason, or if you had to stop your previous study due to a serious side effect.

As this is an extension study, you will continue to receive etrasimod. You will have regular visits to your study clinic, which will involve check-ups with the doctor, blood tests, and discussions about how you're feeling and any changes in your ulcerative colitis or any side effects. It’s important that you keep taking your study medicine as instructed. The specific number and timing of visits will be explained by the study team, but they are designed to continuously monitor your health, how the medicine is working, and to ensure your safety throughout the study’s duration. The total duration of your participation in this extension study will be discussed with you.